Arrowhead Pharmaceuticals Inc (ARWR) — Capital Reinvestment Ratio
Latest as of September 2025:
0.37x
Arrowhead Pharmaceuticals Inc (ARWR) has a Capital Reinvestment Ratio of 0.37x as of September 2025, meaning it reinvests 0% of its operating cash flow ($20.49 Million) in capital expenditures ($7.49 Million). See Arrowhead Pharmaceuticals Inc (ARWR) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.37x
Capex / Operating Cash Flow
Operating Cash Flow
$20.49 Million
USD
Capital Expenditures
$7.49 Million
USD
Data as of
Sep 2025
Most recent filing
Arrowhead Pharmaceuticals Inc Capital Reinvestment Ratio (2019–2025)
This chart tracks Arrowhead Pharmaceuticals Inc's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Arrowhead Pharmaceuticals Inc (2019–2025)
Year-by-year Capital Reinvestment Ratio for Arrowhead Pharmaceuticals Inc from 2019 to 2025. For live market cap and broader valuation context, see ARWR market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | $179.55 Million | $22.67 Million | ▼ -8.3% |
| 2021 | 0.14x | $171.22 Million | $23.57 Million | ▲ +98.4% |
| 2019 | 0.07x | $173.03 Million | $12.00 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow